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ABSTRACT
Using accuracy measures alone to compare diagnostic tests may be unconvincing to clinicians.
The diagnostic test accuracy is commonly evaluated in clinical performance based on its
classification accuracy (specificity, sensitivity, negative and positive likelihood ratio) or its
predictive values (negative and positive predictive value). However, these accuracy measures do
not entirely account for the clinical and health economic consequences of diagnostic errors. The
limitation of these measures is that one test may have a better sensitivity and worse specificity
than another test. Comparing tests on benefit-risk is another approach where benefits and risks
are put on the same scale to determine test benefits and clinical consequences of the diagnostic
errors. Consequently, evaluating diagnostic tests based on benefit-risk involves both the tests’
accuracy and the clinical implications of the diagnostic errors. Diagnostic tests are commonly
classified into two stages: either positive or negative for a clinical condition (diseased or nondiseased). However, some diseases have more than two stages, such as Alzheimer’s. In diseases
with more than two stages, the benefits and risks of the clinical consequences could differ from
stage to stage. I could not find any investigations to account for the difference in benefits and
risks of tests with more than two stages in the literature. The benefit to cost values for each stage
of the disease could be different. This dissertation extends the net benefit approach of evaluating

diagnostic tests in binary disease cases to multi-stage clinical conditions. Consequently, I extend
the diagnostic yield table to multi-stage clinical conditions. I develop a decision process based on
net benefit for evaluating diagnostic tests. The decision process provides additional interpretation
for rule-in or rule-out clinical conditions and their adverse consequences from unnecessary
workups in multi-stage diseases. Numerical examples, as well as real data, are provided to
illustrate the proposed measures.
INDEX WORDS: Loss function, Diagnostic yield table, Relative net benefit, Clinical utility,
Benefit-risk, Medical diagnostics yield, Decision theory, Alzheimer’s disease.
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CHAPTER 1
INTRODUCTION
Diagnostic tests play a significant role in patients’ health care, including medical
diagnosis, screening tests, appropriate therapy, research, and health policy. There are mainly
three purposes of performing a diagnostic test, namely, to provide reliable information about a
patient's health condition, to influence the treatment plan for the patient from health care
providers, and to understand that diseases have mechanisms and natural history of progress
within the body via research (McNeil & Adelstein, 1976; Sox Jr et al., 1989; Zhou, McClish, &
Obuchowski, 2009). A test can serve these purposes only if the health care provider knows the
parameters and conditions of the disease and how to interpret them. This information is acquired
by assessing the test's diagnostic accuracy, which is simply the ability of a test to discriminate
between subjects, between diseased or non-diseased, providing a solid understanding of patients’
health conditions. When a diagnosis is accurate and made promptly, a patient has the best
opportunity for a positive health outcome. Clinical decision-making has been tailored to a correct
understanding of the patient's health problem, ultimately improving healthcare for all patients
(Holmboe & Durning, 2014). Also, diagnostic information often influences public policy
decisions, such as setting payment policies, resource allocation, and research priorities (Jutel &
illness, 2009; Rosenberg, 2002; World Health Organization [WHO], 2012).
While a perfect diagnostic test discriminates between diseased and non-diseased subjects
completely, in reality, it is hard to achieve. A diagnostic test can only partially distinguish
between subjects with or without the disease. Furthermore, the clinical consequences of
diagnostic error are required for a diagnostic test or continuous biomarker in making a diagnostic
decision in the case of binary or ordinal disease stages.
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A diagnostic test result does not accurately represent the patient’s condition because
diagnostic tests rarely have perfect accuracy. Accuracy refers to the probability of the test result
that ultimately reflects the actual disease state. Developing quantitative methods to measure
diagnostic accuracy and clinical consequences is essential. Some of the well-established
techniques of diagnostic accuracy before test measures, such as sensitivity (Se or TPR) and
specificity (Sp or TNR), Youden index, the area under the ROC curve (AUC), and diagnostic
odds ratio (DOR) are used to assess the discriminative property of the test. Other methods of
diagnostic accuracy used after test measures are likelihood ratios (LRs) and predictive values
(PPV and NPV), which help assess its predictive ability.
Different measures of diagnostic accuracy have various aspects of use based on the
purpose of diagnostic procedures. Some diagnostic accuracy measures assess the ability to
differentiate between the non-diseased and the diseased, and others measure its predictive ability.
Diagnostic accuracy measures are also susceptible to the spectrum of diseases and the tested
population. It is essential to know which measure to use under what conditions and interpret
these measures carefully. Some studies have examined the efficiency of different diagnostic tests,
but it is hard to find test results that are always accurate in reality (Akobeng, 2007; Altman &
Bland, 1994; Deeks & Altman, 2004; Margaret Sullivan Pepe, 2003; A.-M. Šimundić, 2009;
Wong & Lim, 2011; Zhou et al., 2009). In misclassification, a medical diagnostic test positively
affects a subject who does not have the disease, and a diseased subject may be diagnosed as nondiseased (Margaret Sullivan Pepe, 2003; Zhou et al., 2009). Diagnostic accuracy is the ability to
discriminate between non-diseased and diseased or non-diseased and different stages of a
particular disease state. Health care professionals need to assess better the performance of
diagnostic tests on discriminating patients with and without the disease of interest to determine
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the actual stage of the patient's condition and make treatment plans for their patients. It is
essential to use accurate medical tests and thus avoid error, unnecessary suffering, and expense.
Many measures for diagnostic accuracy have been developed to describe the performance of a
biomarker for binary scale disease. Sensitivity and specificity are the correct classification rates,
and false-positive rate (FPR) and false-negative rate (FNR) are the misclassification rates among
these measures

(Margaret Sullivan Pepe, 2003; Zhou et al., 2009). While sensitivity and

specificity are used to maximize correct classification rates, the FPR and FNR minimize
misclassification rates.
In medical diagnosis, the sensitivity of a test is the ability of a test to accurately detect
when an individual has a disease. The specificity of a test is the ability to accurately detect an
individual as disease-free who has no disease. A high sensitivity test helps rule out disease if a
person tests negative. A high specificity test helps rule a condition if a person tests positive. A
diagnostic test identifies the presence or absence of a specific disease when a subject shows
significant disease symptoms. The diagnostic test is an essential determinant for health care
providers to decide whether to give treatments for the disease, especially when the treatments are
invasive or harmful procedures, such as chemotherapy and radiotherapy (Gilbert, Logan, Moyer,
& Elliott, 2001). Sometimes the diagnostic test itself has consequences, including an invasive
procedure, such as a biopsy, or introducing energy into the body, as with radiation, using an Xray. A screening test is designed to identify asymptomatic subjects at sufficient risk of the
disease who have not received medical attention or who do not warrant further health
interventions among the population (Gilbert et al., 2001). Commonly, the diagnostic test is
performed after a screening test to make a confirmed diagnosis. Different tests are carried out to
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discriminate between diseased and non-diseased conditions based on sensitivity and specificity
measures.
The Receiver Operating Characteristic curve (ROC) and the area under the ROC curve
(AUC) provide brief measures associated with single sensitivity and specificity pairs by
including all the decision thresholds. Mo (2020) states that some of the steps integrate sensitivity
and specificity into a single index-like accuracy called diagnostic effectiveness. For example,
diagnostic odds ratio (OR) and Youden index overlap measure (H. M. Samawi, Yin, Rochani, &
Panchal, 2017) and KL divergence (Lee, 1999). The OR and the Youden index do not depend on
disease prevalence like sensitivity and specificity. These measures could quickly transfer results
from one study to another with a different disease prevalence in the population. But these
measures are affected by the spectrum of a disease, such as a disease severity, phase, stage, and
comorbidity (Zhou et al., 2009).
On the other hand, accuracy is affected by disease prevalence (A.-M. J. E. Šimundić,
2009; Zhou et al., 2009). The accuracy of a test increases as the disease prevalence decreases
with the same sensitivity and specificity. It means that the accuracy estimated from a population
cannot be generalized to other populations with different disease prevalence. In addition to these
measures introduced above, another type of diagnostic test accuracy measure is predictive
accuracy, including the negative and positive predictive value (NPV and

PPV), respectively,

and diagnostic likelihood ratios (LRs) (A.-M. Šimundić, 2009; Zhou et al., 2009). Predictive
values have significant clinical implications for a diagnostic test. Although measures like
sensitivity and specificity estimate the probability of the disease in patients, they cannot answer
how likely it would be for patients to receive positive or negative test results. Predictive values
are the measures that provide information about the probability that a test result gives a correct
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diagnosis. Given a positive test result, a positive predictive value (PPV) shows the probability of
having the state or disease of interest in a subject. That means PPV represents a proportion of
patients with positive test results among total subjects with positive results. A negative predictive
value (NPV) is the probability that a subject receives a negative effect yet does not have the
disease of interest (Altman & Bland, 1994; Wong & Lim, 2011). It means that NPV represents a
proportion of subjects without the disease, having a negative test result in a total of subjects with
negative test results. Unlike sensitivity and specificity, predictive values are highly dependent on
the disease prevalence, which cannot be generalized among different populations with different
disease prevalence. Compared to predictive values, LRs can also provide information about the
probability that a subject can be correctly diagnosed; nevertheless, LRs do not depend on
prevalence as the predictive values, and they apply to other clinical settings for the same disease
(Boyko, 1994; Deeks & Altman, 2004). LRs are also the best indicator for rule-in or rule-out of
the diagnosis (Boyko, 1994; Deeks & Altman, 2004; Gilbert et al., 2001). Mainly, a rule-in test
assesses if the results from a diagnostic test will include the possibility that a subject has the
disease of interest. A high specificity test's positive response makes the patient more likely to
have the condition since it is specific. With more significant, more considerable sensitivity, a
rule-out test emphasizes assessing if test results will exclude the possibility that a subject is nondiseased. A high sensitivity test's negative response makes the patient more likely not to have the
disease since it is sensitive.
Traditionally, medical diagnostic tests are evaluated using accuracy measures of the
discrimination ability of the test and its predictive ability. However, these accuracy measures do
not entirely account for clinical and health economic contexts. Gail and Pfeiffer (2005) argue
that decision theory methods could provide more relevant clinical application outcomes. H.
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Samawi, Chen, Ahmed, and Kersey (2021) state that these methods evaluate risk models in
treatment decisions by conveying costs and benefits on the same scale that involves the accuracy
of diagnostic tests and clinical consequences of diagnostic errors using utilities (Rapsomaniki,
White, Wood, Thompson, & Emerging Risk Factors, 2012).
Furthermore, as G. Pennello, N. Pantoja-Galicia, and S. Evans (2016a) argue, evaluating
a diagnostic test based on benefit-risk involves both the test's accuracy and the clinical
consequences of diagnostic errors. Three things, clinical setting, the intended use of diagnostic
tests, and the characteristics of the population on whom they will be used, may affect the
evaluation of the clinical consequences of false positive and false negative test errors. The
diagnostic test may have clinical effects (e.g., biopsy). Other health economics investigators may
consider the test's cost and the consequential costs of treating positive test subjects (Tsalik et al.,
2016).
In the literature, I find some studies that compare diagnostic tests based on benefit-risk in
two-stage diseases. They describe methods for evaluating the benefit-risk of a binary diagnostic
test based on its diagnostic accuracy from a clinical performance study and external information
on clinical consequences (Pennello et al., 2016a).
Pennello et al. (2016a) use a benefit-risk approach based on a decision-theoretic
framework to compare diagnostic tests or biomarkers. Their method assigns losses to
misclassifications (i.e., false-positive and negative) and gives utilities to correct classifications
(true positive and true negative). Their theory provides different interpretations of quantities in
the diagnostic yield table. It indicates that a weighted accuracy measure proposed previously
(Evans et al., 2016) could be interpreted as a relative utility measure. They define comparable
utility measure as the test's expected utility close to a perfect test. They also describe expected
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benefits from testing and net benefits relative to a perfect test. Evans et al. ( 2016 ) indicate that
the expected benefit of a test and the net benefit close to an ideal test are similar to the expected
benefit measures proposed for risk prediction models (S. G. Baker, Cook, Vickers, & Kramer,
2009; S. G. Baker & Kramer, 2012; S. G. Baker, Van Calster, & Steyerberg, 2012; S. G. J. J. J. o.
t. N. C. I. Baker, 2009; Gail & Pfeiffer, 2005; Vickers & Elkin, 2006) and (Margaret S Pepe et
al., 2016).
Most medical diagnostic tests are commonly classified into two stages: either positive or
negative for a clinical condition (diseased or non-diseased). However, some diseases have more
than two stages in clinical practice, such as Alzheimer's. Alzheimer's disease has four stages,
including preclinical stage, early-stage (mild), middle stage (moderate), and late-stage (severe)
(Alzheimer's Association, 2019; Johns Hopkins Medicine, 2019a). A measure that can
discriminate among more than two stages is desired for this type of disease. But, I could not find
any studies comparing diagnostic tests based on the benefit-risk of multi-stage disease tests in the
literature. Clinical utility values for each stage of the disease could be different. Therefore, this
dissertation extends the net benefit approach of evaluating diagnostic tests to multi-stage clinical
conditions. Consequently, I extend the diagnostic yield table to multi-stage clinical conditions. I
develop a decision theory based on the net benefit of evaluating diagnostic tests that provide
additional interpretation for rule-in or rule-out clinical needs and their adverse consequences
from unnecessary workups for multi-stage diseases.
In this research, we generalize the net benefit of a diagnostic test, from two-stage to
multi-stage diseases, as an evaluation of a diagnostic test that involves both the test's accuracy
and the clinical consequences of diagnostic error. This evaluation sums up the rule-in or rule-out
information in all stages, and it comprehensively evaluates the correct classification rates in all
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phases of a multi-stage disease. Overall, the generalization of a diagnostic test based on benefitrisk combines correct classification rates and misclassification rates based on benefit-risk for
conditions with more than two stages and simultaneously emphasizes the rule-in, rule-out
potentials for diagnosis in all stages.
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CHAPTER 2
LITERATURE REVIEW
Traditionally, medical diagnostic tests are evaluated using accuracy measures based on
the discrimination ability of the test. However, using accuracy measures alone to compare
diagnostic tests or biomarkers may be unconvincing for clinicians. Comparing tests based on
benefit-risk may be more conclusive because it involves the accuracy of the test and the clinical
consequences of diagnostic error. Many factors, such as clinical setting, the intended use of the
test, and the population on whom it will be used, play an essential role in evaluating the clinical
consequences of false positive and false negative test errors. Sometimes, the test itself has a
clinical implication. For example, it may involve an invasive procedure (e.g., biopsy) or
introduce energy into the body, such as radiation (e.g., X-ray computed tomography (CT) scan).
A health economics analysis may also consider the decision-analytics framework and the
potential cost-effectiveness of working up positive test subjects (Tsalik et al., 2016).
To compare diagnostic tests or biomarkers on accuracy measures alone may not be
convincing to clinicians. The diagnostic test accuracy is commonly evaluated in a clinical
performance based on its classification accuracy (specificity, sensitivity, negative and positive
likelihood ratio) or its predictive values (negative and positive predictive value). However, these
evaluations can sometimes be insufficient for comparing the clinical consequences of the two
tests. The primary constraint of these measures is that one test may have a better sensitivity and
worse specificity than another test.
ROC and Youden indices are prevalent, essential measures and the most popular tools for
binary classification. They describe different aspects of a biomarker in diagnostic studies for test
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evaluation. Both measures are built based on the four fundamental estimates of diagnostic
accuracy: sensitivity, specificity, FPR, and FNR. Diagnostic accuracy measures are susceptible
to the characteristics of the population in which the test accuracy is evaluated. Some estimates of
diagnostic accuracy highly depend on the prevalence of the disease of interest, while others are
susceptible to the spectrum of the disease in the studied population (A.-M. J. E. Šimundić, 2009).
The four basic measures (Sensitivity (TPR), Specificity (TNR), False Positive Rate (FPR), and
False Negative Rate (FNR)) are not affected by the prevalence of the disease of interest. Still,
their values are intrinsic to the diagnostic accuracy of a diagnostic test (Zhou et al., 2009). In
other words, these measures are influenced by the disease's spectrum, which is the range of
clinical severity or anatomic extent that constitutes a disease. Moreover, sensitivity and
specificity measures are transferrable from a sample population to other populations with
different prevalence rates. Additionally, sensitivity and specificity are the correct classification
rates of diseased and non-diseased people, correctly categorizing their actual states. They provide
a holistic picture of a diagnostic test.
The ROC Curve was first introduced in the analysis of radar signals. Later on, it was
employed in signal detection theory during World War II. It opened the door to new research to
increase the prediction of correctly detecting Japanese aircraft from their radar signals after the
attack on Pearl Harbor in 1941(Egan & Egan, 1975; Green & Swets, 1966). Later, ROC was
applied to radiological, psychophysical, and epidemiological studies (Aoki, Watanabe, Furuichi,
& Tsuda, 1997; Hsiao et al., 1989; Metz, 1989). ROC curve potentials in medical diagnostics
were recognized as early as the 1960s (Lusted, 1960). Previous studies have systematically
reviewed and illustrated the application and evaluation of diagnostic accuracy using ROC
(Margaret Sullivan Pepe, 2003; Swets & Pickett, 1982; Zweig & Campbell, 1993).
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Sometimes, it is not feasible to construct ROC, and a summary index becomes a critical
measure to summarize its information. AUC is the most widely used summary statistic of ROC
and is computed by taking the integral of ROC statistics from 0 to 1 (Fawcett, 2006). AUC is a
global measure of diagnostic accuracy that summarizes the test's overall diagnostic accuracy, and
it does not provide information about sensitivity and specificity as a summary index. Moreover,
the ROC curve and AUC have no information about predictive values of rule-in or rule-out of a
test in medical diagnostics.
The Youden index is another prevalent measure for binary classification in diagnostic
accuracy. It is also a global measure, which Youden first proposed in 1950 (Youden, 1950). The
Youden index ( J ) is a statistic that maximizes correct classification rates (i.e., sensitivity and
specificity) and achieves the maximum discrimination between two stages of the disease. The
Youden index also encounters the same issues as ROC and AUC as two diagnostics, with the
same Youden index value having different sensitivity and specificity. It is mostly used to
determine the overall performance, and it does not characterize the rule-in or rule-out
information in diagnosis.
After estimating an optimal cut-point in clinical practice, we need to understand the
implication of the results, such as how likely it would be that the test would provide the correct
diagnosis. The measures that can answer this question are the predictive values (i.e., the PPV and
the NPV) and the LRs, which approach the data from an aspect different from sensitivity and
specificity (Altman & Bland, 1994). PPV of the test is defined as the proportion of subjects with
positive test results who are correctly diagnosed (i.e., true positive results) (Fletcher, Fletcher, &
Fletcher, 2012). Similarly, NPV is the proportion of the cases giving negative test results which
are truly non-diseased (i.e., true negative results) (Fletcher et al., 2012). Although PPV and NPV
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are commonly used in clinical decision-making, they depend on the prevalence of the disease as
they differ in different populations of the same diagnostic test (Altman & Bland, 1994). When
the sensitivity and specificity are fixed, the PPV of the test increases as the underlying
prevalence of the disease of interest increases, whereas the NPV decreases (Wong & Lim, 2011).
When the sensitivity and specificity are fixed, the PPV of the test increases as the underlying
prevalence of the disease of interest increases, whereas the NPV decreases (Wong & Lim, 2011).
Similarly, the PPV of the test decreases as the underlying prevalence of the disease of interest
decreases, whereas the NPV increases. Therefore, the PPV and the NPV of a population cannot
be generalized to a different population.
LRs are another statistical tool to understand diagnostic tests. Compared to PPV and NPV,
LRs do not depend on the prevalence of the disease, and LRs of the same diagnostic test can be
generalized from one population to another population. Additionally, LRs provide information
about the rule-in or rule-outs of a diagnostic test (Boyko, 1994; Deeks & Altman, 2004). Rule-in
or rule-out tests are essential for different health care purposes. For example, the rule-in principle
(specificity) is functional when a toxic treatment of the disease will be initiated if the diagnosis is
confirmed, such as in the use of chemotherapy or combination chemotherapy for malignancies
(Lee, 1999). The rule-out principle (sensitivity) is also helpful when there is a significant penalty
for missing the disease, and the initial treatment is relatively safe, like in the use of screening
tests for tuberculosis or hypothyroidism (Lee, 1999). LRs can be calculated for either positive or
negative test results. It allows health care professionals to determine how much the utilization of
a particular test will alter the probability. A positive LR tells how likely it will be that a diseased
subject will receive a positive test result compared to a non-diseased subject. In contrast, a
negative LR shows how likely it will be that a non-diseased subject will receive a negative test
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result compared to a diseased subject (A.-M. Šimundić, 2009). Note that these measures depend
on the disease prevalence. However, these measures are sometimes not enough to evaluate the
clinical consequences relative to other tests. The shortcoming of using these measures is that a
test may have better sensitivity than another test but have worse specificity. In this case, we can
use a benefit-risk approach where benefits and risks are put on the same scale to decide which
test has better, worse, or about the same benefit-risk trade-off when considering the clinical
consequences of a test.
G. Pennello, N. Pantoja-Galicia, and S. J. J. o. b. s. Evans (2016b) describes benefit-risk
as another approach to determine whether a diagnostic test has better, worse, or the same
outcomes when assessing a test's clinical consequences. Consequently, evaluating diagnostic
tests based on benefit-risk involves both test accuracy and clinical implications of diagnostic
errors. Diagnostic tests are commonly classified into two stages: either positive or negative for a
clinical condition (diseased or non-diseased). A biomarker that can discriminate between
subjects into diseased and non-diseased populations is efficient for diagnosing a disease.
However, some diseases have distinct ordinal stages that existing measures cannot recognize in
diagnostics. Dichotomizing biomarker to binary stages generally combines disease stages,
resulting in the delay in diagnosing patients in the early stage. Failing to diagnose patients in the
early stage of the disease will delay appropriate treatments and cause serious health problems in
the future. Therefore, diagnosing a patient in the early disease stage will allow physicians to
provide early interventions and decrease the progression of the disease. The medical community
has demonstrated high interest in the ability to discriminate diseased populations into different
stages to provide better treatment strategies, such as the identification of mild cognitive
impairment of Parkinson’s disease and the early diagnosis of Alzheimer's disease (Aarsland &
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Kurz, 2010; DAFFNEr & Scinto, 2000). Thus, having the appropriate methods to discriminate
among different stages of a disease is imperative for early clinical interventions, such as early
interventions for breast cancer (Abe et al., 2005; Richards, Westcombe, Love, Littlejohns, &
Ramirez, 1999). A decision-theoretic approach is vital for screening a population for disease and
deciding whether to administer a preventive intervention with adverse or beneficial effects.
Moreover, some frontier studies propose measures generalizing from binary to multistage classification using the ROC, AUC, and Youden index (Nakas, Alonzo, & Yiannoutsos,
2010; Nakas, Dalrymple-Alford, Anderson, & Alonzo, 2013; Brian K. Scurfield, 1996; Brian K
Scurfield, 1998; Xiong, van Belle, Miller, & Morris, 2006). A clinical utility study can be
another approach to evaluate clinical outcomes, which can be improved when the test influences
subject management. But clinical utility studies can be expensive to conduct, take lengthy
follow-up time on subjects, and be challenging to design. A poorly designed clinical utility study
can be inefficient and may not even permit these studies to reveal whether the evaluation of a test
affects clinical consequences (Bossuyt, Lijmer, & Mol, 2000; Hoering, Leblanc, & Crowley,
2008; Simon, 2010). Pennello et al. (2016b) use the benefit-risk approach based on a decisiontheoretic framework to compare diagnostic tests for binary classification as a new measure for
diagnostic accuracy, suggesting it is a better disease diagnostic procedure, in some cases,
compared to the other existing measures. This theory indicates a weighted accuracy measure,
proposed previously by Evans, which can be interpreted as a relative utility measure, with
expected utility close to that for a perfect test (sensitivity = specificity = 1) (Evans et al., 2016).
The comparisons of binary-valued tests based on benefit-risk evaluation (Pennello et al., 2016a)
are similar to recent work in the review of new markers for risk prediction (S. G. Baker et al.,
2009; S. G. Baker & Kramer, 2012; S. G. Baker et al., 2012; S. G. J. J. J. o. t. N. C. I. Baker,
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2009; Gail & Pfeiffer, 2005; Vickers & Elkin, 2006) and diagnosis (Margaret S Pepe et al., 2016).
For example, the relative utility curve (S. G. Baker et al., 2009) is a fraction of the expected net
benefit of perfect prediction, and a risk prediction model obtains it at the optimal cut point.
Similarly, weighted accuracy (Evans et al., 2016) is a fraction of the expected utility of a perfect
diagnostic test that is obtained by an investigational diagnostic test.
Emerging studies of diagnostic accuracy for multi-stage diseases show high demand for
developing a more reliable diagnostic procedure to discriminate among subjects in different
diseased stages accurately (Attwood, Tian, & Xiong, 2014; Li & Fine, 2008; Nakas et al., 2010;
Nakas et al., 2013; Xiong et al., 2006). For example, some chronic diseases, such as Alzheimer’s
disease, kidney disease, and cancers (prostate, lung, colorectal, and ovarian), have more than two
stages in nature and require measures that can identify subjects among stages (Alzheimer's
Association, 2019; Johns Hopkins Medicine, 2019a). Ovarian cancer ranks the fifth leading
cause of cancer death among women in developed countries (Chudecka-Głaz, 2015). It generally
presents in advanced stages with a high case fatality ratio (CFR) but has favorable survival rates
if diagnosed earlier. Additionally, clinical symptoms are not well manifested in the early stages
of the disease, resulting in late diagnosis and poor prognosis (Cramer et al., 2011). Some
traditional binary tests cannot directly be used for multi-stage diseases. However, some popular
measures can be extended and are generalized to the multi-stage setting.
To my knowledge, no studies have investigated accuracy measures and the clinical
consequences of medical diagnostic test errors in multi-stage disease settings. Also, the clinical
implications of treating or not treating patients at a different stage of the disease have different
benefit-risk consequences. Therefore, this dissertation intends to expand the net benefit approach
for evaluating medical diagnostic tests for a multi-stage clinical condition. And consequently,
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this study will provide additional interpretation, using the net benefit approach for rule-in or ruleout clinical conditions and their adverse consequences from unnecessary workups in multi-stage
diseases.
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CHAPTER 3
METHODS
This chapter provides an overview of some related methods for evaluating the benefitrisk of a binary diagnostic test based on its diagnostic accuracy from a clinical performance
study and external information related to clinical consequences (see Pennello et al. (2016a)).

3.1 Introduction
For most medical diagnostic testing, biomarkers are dichotomized to classify subjects in a
binary manner, either positive or negative for a clinical condition (positive for diseased or
negative for non-diseased). The test is evaluated for its diagnostic accuracy by comparing test
negative and positive results (T = 0,1) for agreement with the absence and presence of the
clinical condition (D = 0,1), as determined by a clinical reference standard or best available
method.
Pennello et al. (2016a) indicate that comparing diagnostic tests based on accuracy alone
could be inconclusive. They propose that comparing tests based on benefit-risk may be more
conclusive because clinical consequences of diagnostic error are considered. For benefit-risk
evaluation, they present diagnostic yield as the expected distribution of subjects with true
positive, false positive, true negative, and false-negative test results in a hypothetical population.
They construct a table of diagnostic yield, which indicates the number of false-positive subjects
experiencing adverse consequences from unnecessary workup. Then they develop a decision
theory for evaluating tests. Pennello et al. (2016a) argue that their progressive approach provides
additional interpretation to quantities in the diagnostic yield table. This approach also indicates
that the expected utility of a test relative to a perfect test is a weighted accuracy measure. The
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average sensitivity and specificity weighted for prevalence and relative importance of falsepositive and false-negative testing errors are also interpretable as the cost-benefit ratio of treating
non-diseased and diseased subjects. These researchers also propose plots of diagnostic yield,
weighted accuracy, and relative net benefit of tests as functions of prevalence or cost-benefit
ratio. For example, they illustrate these concepts with hypothetical screening tests for colorectal
cancer, with positive test subjects referred to colonoscopy.
Furthermore, Pennello et al. (2016a) argue that the benefit-risk evaluation of a diagnostic
test involves not just the accuracy of the test but the clinical consequences of diagnostic error.
They explain that assessing the clinical implications of false positive and false negative test
errors depends on the clinical setting, the intended use of the test, and the population on whom it
will be used. Sometimes, the test itself has clinical consequences. For example, these
consequences may involve an invasive procedure, such as a biopsy, or introducing energy into
the body as with radiation, using an X-ray. These researchers argue that a health economics
analysis might also consider the cost of testing and downstream costs of working up positive test
subjects (Tsalik et al., 2016).
A diagnostic test classifies subjects as either positive or negative for a clinical condition
(e.g., disease absence or presence). Also, a diagnostic test predicts a future binary state (e.g.,
susceptibility or resistance of a microbe to an antimicrobial drug). Diagnostic accuracy is
evaluated in a clinical performance study for its classification accuracy (e.g., specificity,
sensitivity, negative and positive likelihood ratio) or its predictive accuracy (e.g., negative and
positive predictive value – NPV, PPV). However, these evaluations can sometimes be
insufficient for examining the clinical consequences of the test relative to other tests. For
example, one test may have better sensitivity but actually have worse specificity than another
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test. Thus, based on such accuracy measures alone, a determination of whether a test has better,
worse, or about the same benefit-risk tradeoff as another test can be equivocal.
A clinical utility study should be performed to evaluate the clinical consequences of a test
in order to show whether clinical outcomes can be improved when the test is used in order to
influence subject management. However, there could be limitations to performing clinical utility
studies. They could be expensive, require lengthy subject monitoring, and design could be
complex. A poorly designed clinical utility study can be inefficient and may not even permit an
evaluation of test effect on clinical outcome (Bossuyt et al., 2000; Hoering et al., 2008; Simon,
2010). Additionally, such clinical utility data are usually not available to a regulatory agency
when deciding whether or not to approve a test for the market.

3.2. Test Accuracy
Pennello et al. (2016a) describe hypothetically comparing a standard test (S) and a new
test (T) used to screen for colorectal cancer (CRC) as follows: consider a new diagnostic test that
indicates subjects as test negative or positive for a clinical condition, (e.g., disease). The test is
evaluated for its diagnostic accuracy by comparing test negative and positive results (T=0, 1) for
agreement with the absence and presence of the clinical condition (D = 0, 1), as determined by a
clinical reference standard or best available method. These researchers consider comparing the
new test with a standard test, indicating subjects as negative or positive (S=0, 1). They provide
the following example: the new test has better sensitivity (0.90 vs. 0.75) but worse specificity
(0.85 vs. 0.95) than the standard. However, one of the tests could still be declared better than the
other if its negative and positive predictive values (NPV, PPV) are better. PPV is monotone since
it increases the positive diagnostic likelihood ratio PLR = Se/(1−Sp). NPV is monotone,
decreasing the negative diagnostic likelihood ratio NLR = (1 − Se)/Sp. Thus, the new test would
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have better NPV and PPV for the same prevalence as the standard test if its NLR is smaller and
its PLR are larger. Pennello et al. (2016a) suggest using the following graph that shows an
example of visual interpretation of the likelihood ratio graph (Figure 3.1), a helpful display
proposed originally by Biggerstaff (2000). The graph has the same axes as the ROC plot. The
coordinate of both the true and false-positive fractions of the standard test is plotted in the graph,
with two lines drawn through it to the points (0,0) and (1, 1). The slope of the lines through (0,0)
and (1,1) are PLR and NLR, respectively. These two lines define four regions in which the
coordinate of the new test could lie. In this case, the new test falls in region A, indicating that it
is better at detecting the absence of CRC than the standard test. However, it is worse than the
standard test at detecting the presence of CRC because, respectively, its PLR is worse (smaller),
while its NLR is better (smaller). In summary, evaluating which test is better based on test
accuracy alone is equivocal.

Figure 3.1. Likelihood Ratio Graph: Regions of Comparison (source: Pennello et al., 2016)
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3.3 Diagnostic Yield
The measures of diagnostic accuracy are all based on conditional probabilities.
Classification accuracy measures (Se, Sp, NLR, PLR) are based on the probabilities of test
results conditional on disease status. In contrast, measures of predictive accuracy (NPV, PPV)
are based on probabilities of disease status, conditional on the test result. Likewise, Pennello et
al. (2016a) indicate that they consider their diagnostic yield table to compare two tests based on
benefit-risk, which can provide knowledge on the clinical significance of a test and relate
directly to formal decision-theoretic evaluations of the benefit-risk. They consider the
distribution of false-negative (FN), true positive (TP), true negative (TN), and false-positive (FP)
results in the screening population as the joint probability distribution of disease status and test
results.
Table 3.1. Equivalent Loss and Utility Functions
(Loss due to the act of testing is assumed to be 0)
Loss Functions
Test

D=0

D =1

T=0

r00

r01

T=1

r10

r11

Utility Functions
Test

D=0

D =1

T=0

−r00

−r01

T=1

−r10

− r11
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The parameters of the diagnostic yield table (3.1) designated by joint probabilities'
distribution are then given as
D =0

T = 0  0 00
Y =
T =1  010

D =1

1 01 

111 
,

(3.1)

with Disease D= d=0 or 1(disease negative or disease positive), Test T=t=0 or 1 (test negative or
test positive), Prevalence d = Pr( D = d ) and

 td = Pr(T = t D = d ) .

In general, when comparing the diagnostic yield tables of some tests, we can quantify the
number of FP subjects harmed from unnecessary additional workup involving an invasive
procedure (e.g., colonoscopy) and the number of FN subjects harmed by lack of further workup.
The harm associated with an FN result includes not receiving necessary treatment for a disease,
which then may progress unattended. The disease is typically aggressive in some settings, and all
FN subjects are harmed by lack of detection. In other settings, the disease is typically slowly
progressing, and harm from delay in detection may be weighed against competing risks, as may
occur with older men with early-stage prostate cancer, who may die of other causes (Pennello,
2016).
Based on test accuracy alone, the new test may seem more worthwhile than a standard
test because of its superior sensitivity to detecting the disease. Yet its inferior specificity of the
new test may have clinical consequences for many subjects in the intended use population who
will falsely test positive. The diagnostic yield table facilitates a quantitative discussion of
questions related to these consequences.
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3.4 Decision-Theoretic Evaluation
A diagnostic yield table and plots (Table 3.1) provide information about the clinical
significance of test results. This information will directly impact formal decision-theoretic
evaluations of benefit-risk.
3.4.1 Expected Loss
If d= 0, 1 indicates disease absence, presence, and t= 0, 1 indicates the binary test results
(negative, positive), Pennello et al. (2016) express the loss of a test as follows,

L(t , d ) = L0 (d ) + t ( L1 (d ) − L0 (d )) ,

(3.2)

where, L0 (d ) and L1 (d ) are the losses ascribed to negative and positive test results, respectively.
This is related to the incorrect classification of stages 0, 1, and 2 of a disease condition. We
consider ascribing a loss rtd to the binary test result T = t on a subject with disease state D = d
with d= 0, 1 (absent and present disease stages), and t = 0, 1 (negative and positive test result).
General loss functions follow;

L0 (d ) = (1 − d )r00 + dr01
L1 (d ) = (1 − d )r10 + dr11 ,
With the loss of a test (3.2)
L(t , d ) = L0 (d ) + t[(1 − d )(r10 − r00 ) − d ( r11 − r01 ))]
= L0 (d ) + t[(1 − d )C − dB],
L(t , d ) = B{L0 (d ) / B + t[(1 − d )r − d ]}

(3.3)

(3.4)
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In expression (3.3), the loss depends on test result t only through C and B, with B = r01 − r11 and

C = r10 − r00 . In expression (3.4), the loss function is proportional to one, which depends on test
result t only through r, where r =

C
= FP : FN loss ratio=TN:TP utility ratio.
B

3.4.2 Expected Utility
Losses L0 (d ) and L1 (d ) are defined based on incorrect binary test classifications (false
negative, false positive), and utilities U 0 (d ) and U1 (d ) are credited to correct test classifications
(true negative, true positive). Pennello et al. (2016a) present the “utility” of the test as:

U (t , d ) = (1 − t )U 0 (d ) + tU1 (d )

= U 0 (d ) + t (U1 (d ) − U 0 (d )).

(3.5)

The utility function is simply the negative of the loss. So, the expected loss is the
negative of the expected utility ( U1 (d ) − U 0 (d ) = L0 (d ) − L1 (d ) ). This equality occurs if, for
instance U1 (d ) = L0 (d ) = d and U 0 (d ) = L1 (d ) = (1 − d )r . Thus, r is interpretable as the relative
loss ratio of false-positive to false-negative test results and the relative utility ratio of true
negative to true positive test results. Under these utility functions, Pennello et al. (2016) express
the utility functions as

U (t, d ) = (1− t )(1− d )r + td ,

(3.6)

and hence the expected utility for the test as

E  EU (t , d ) = 0 00 r + 111

(3.7)

Upon examination of utility and loss functions, respectively, B and C have been
interpreted as the overall net benefit and net cost of treating test positive subjects with and
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without disease, respectively (S. G. Baker et al., 2012; Pauker & Kassirer, 1975; Margaret S
Pepe et al., 2016; Vickers & Elkin, 2006). Upon examining the utility function, r may be
interpreted as the TN: TP utility ratio and the FP: FN loss ratio.
3.4.3 Net Benefit
The net benefit of a test compared with a random test with test positive probability τ is
defined as the difference in expected utility between the test (E) and the random test ( E ).

NB = E − E

(3.8)

The net benefit of the test over never treating a subject is NB0 a difference in expected
utility from the always negative test. The net benefit over always treating a subject is NB1 a
difference in expected utility from the always positive test. The relative net benefit of a test is
defined as

RNB = ( E − E ) / ( E perf − E )

(3.9)

which scales the net benefit to have a maximum of 1 relative to the net benefit of a perfect test.
The following graphs (Figure 3.2 and Figure 3.3) show a visual interpretation of the relative net
benefit over never treat and always treat policies as a function of relative importance ratio r,
which provide an overall comparison of the new and standard tests (Pennello et al., 2016a).
Findings from these plots indicate that relative net benefit over the never treat policy is
noticeably worse for the new test than the standard test over an extensive range of r values.
However, the relative net benefit over the always treat policy is slightly worse than the standard
test over an extensive range of r values. Thus, the two tests can be considered comparable in
settings where prophylactic treatment is practiced in place of testing.
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Figure 3.2. Relative Net Benefit over Never Treat by Cost-Benefit Ratio r (source: Pennello et al.,
2016)

Figure 3.3. Relative Net Benefit over Always Treat by Cost-Benefit Ratio r (source: Pennello et al., 2016)
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3.4.4 Choosing r
Pennello et al. (2016a) indicate that, at a minimum, the expected utility of the new test
should be greater than the expected utility of any non-informative test that renders a positive test
result at random with probability  (0    1) . The difference in the expected utility of a test
compared with a random test is called net benefit. The test has a positive net benefit compared
with any random test if the FP: FN relative importance ratio r 

P1
 1 .
(1 − P1 )

It is used where pt = Pr( D = 1 T = t ) is the predictive value of test results T = t for the disease. In
other words, the test is valid (better than any random test) only for choices when r  1 .
The note 1 =

1 11
is the reciprocal of the FP to TP ratio. Thus, information should
0 (1 −  00 )

be acquired based on choices of r that are acceptable for the test. Equivalently,

(11 / (1 − 00 )  (r /  ) ,
Where, 1 =

1
is the pre-test odds of disease. Noting that a test is informative only if the ratio of
0

its true to false-positive fraction (11 /1 −  00 )  1 , we find that r   is an additional constraint
on valid choices of r. Thus, in terms of reducing expected loss relative to the trivial test, the new
test is valid only for FP: FN loss ratios

r  ( ,1 )
Thus, 1 =

1 11
is the reciprocal of the FP to TP ratio. Also, θ is the reciprocal of the FP to
0 (1 −  00 )

TP ratio for a trivial test that classifies everyone as test positive.
This dissertation proposes extending the net benefit approach of evaluating diagnostic
tests to multi-stage clinical conditions. This new approach uses the diagnostic yield table, all the
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classification information, and both correct and incorrect classification probabilities. Also, this
approach aims to demonstrate the application of the net benefit approach to evaluating diagnostic
tests for multi-stage clinical conditions based on their diagnostic accuracy from a clinical
performance study, along with external information on clinical consequences. More details of the
proposed criterion in the multi-stage setting are discussed in Chapter 4.
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CHAPTER 4
NET-BENEFIT APPROACH FOR COMPARING DIAGNOSTIC
TESTS OF MULTI-STAGE DISEASES
This dissertation proposes extending the net benefit approach of evaluating diagnostic
tests to multi-stage clinical conditions (k>2). Consequently, I extend the diagnostic yield table
presented by Pennello et al. (2016a) to multi-stage clinical conditions. I develop a decision
theory based on net benefit for evaluating diagnostic tests that provide additional interpretation
for rule-in or rule-out clinical needs and their adverse consequences from unnecessary workup in
multi-stage diseases.

4.1 Introduction and Preliminaries
As

in

Samawi

et

al.

(2021),

we

define

a

class

of

probabilities pbd

b = 0,1,..., k − 1; d = 0,1,..., k − 1 for classifying a randomly selected subject in the b th test class,
given the subject is in the d th stage of the disease (In general, when the number of the test
outcomes is equal to the number of the disease stages). Based on the continuous biomarker X,
cut-points c = (c−1 = −, c0 , c1 ,..., ck −2 , ck −1 = ) are needed to diagnose the disease’s k-stage
(Patients with biomarker values within the range of cb−1  X d  cb , b = 0,1,..., k − 1, diagnosed as
stage b). Let X d denote the d th disease stage (determined by the gold standard) with pdf and CDF

f d ( x) , Fd ( x) respectively. Then  bd defines as

 b,d = P(cb −1  X d  cb | D = d ) = Fd (cb ) − Fd (cb −1 ) = P(T = b | D = d ),

(4.1)

b = 0,1,..., k − 1; d = 0,1,..., k − 1 where T is the random variable of the test results, and D is the

random variable for the disease stage's true classification. Now we can define the probability
classification matrix as follows:
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D = 0 D = 1 ... D = k − 1

 01 ...  0( k −1)  T = 0
  00
 
 11 ...  1( k −1)  T = 1
 10
 .
.
.
. 
.
Ρ=
.

.
.
.
.
.


 .
.
.
. 
.


 ( k −1)0  ( k −1)1 ...  k −1( k −1)  T = k − 1
k −1

Noting that


b =1

bd

(4.2)

= 1, d = 0,1, 2,..., k − 1. Also, let d = p( D = d ); d = 0,1, 2,..., k − 1be the

prevalences of the dth disease stage.
To show how to calculate the classification matrix (4.2), when we have a continuous
biomarker, we introduce the case for the number of three stages of disease condition to simplify
the discussion. When cut-points are specified, one can use the empirical or kernel smoothing
approach to estimate the distribution function to find the classification matrix (4.2). For k=3, the
classification matrix in (4.2) reduces to
D = 0 D=1 D=2
 00  01  02  T = 0 
F0 (c1 )
F1 (c1 )
F2 (c1 )




Ρ =  10  11  12  T = 1 =  F0 (c2 ) − F0 (c1 ) F1 (c2 ) − F1 (c1 ) F2 (c2 ) − F2 (c1 )  .
 20  2,1  22  T = 2  1 − F0 (c2 )
1 − F1 (c2 )
1 − F2 (c2 ) 

4.2 Three-stage Diseases Diagnostic Yield Tables
Following Pennello et al.'s (2016) definitions, we define the diagnostic yield table, which
can provide knowledge about the clinical significance and relate these findings directly to formal
decision-theoretic evaluations of the benefit-risk. I assign losses to misclassification or utilities to
correct classification as in table 4.1.
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Table 4.1. Equivalent Loss and Utility Functions
(Loss due to the act of testing is assumed to be 0)
Test

D=0

D =1

D =2

T=0

r00

r01

r02

T=1

r10

r11

r12

T=2

r20

r21

r22

D =1

D =2

Test

D=0

T=0

−r00

−r01

−r02

T=1

−r10

− r11

−r12

T=2

−r20

−r21

−r22

However, the parameters of the diagnostic yield table (4.1) designated by the joint
probabilities' distribution are then given as

D=0

T = 0  0 00
Y = T =1  
 0 10
T = 2  
 0 20

D =1

D=2


2 02 

  .
1 11
2 12 

  
1 21
2 22 



1 01

 

(4.3)

I have two major categories for the test t=0 or 1 (test negative or test positive for any
stage of the disease). Also, I have two major categories: disease d=0 or 1 (absence or presence,
for any stage of the disease). I can identify the loss functions
1- L0 (d ) = (1 − d )r00 + dr01 + dr02
2- L1 (d ) = (1 − d )r10 + dr11 + dr12
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3- L2 (d ) = (1 − d )r20 + dr21 + dr22 .
Similarly, I can extend the diagnostic yield tables to k-stage diseases.

4.3 Expected Loss Function
As in Pennello et al. (2016), we will express the loss of a test as follows.

L(t , d ) = L0 (d1 ) + t ( L1 (d ) + L2 (d ) − L0 (d )) ,

(4.4)

which is related directly to the incorrect classification of stages 0, 1, and 2 diseases. I consider
ascribing a loss rtd to the three-stage disease test result T = t on a subject with disease state D =
d where d= 0, 1 (absent and present disease stages), and t = 0, 1 (negative and stage 1 or 2 of a
disease [positive test result]).
Therefore, from the table (4.1), I can get

L(t , d ) = L0 (d ) + t[ L1 (d ) + L2 (d ) − L0 (d )]
= L0 (d ) + t[(1 − d )r10 + dr11 + dr12 + (1 − d )r20 + dr21 + dr22
− ((1 − d )r00 + dr01 + dr02 )]
= L0 (d ) + t[(1 − d )(r10 + r20 − r00 ) + d (r11 + r12 + r21 + r22 − r01 − r02 )]

(4.5)

= L0 (d ) + t[(1 − d )(r10 + r20 − r00 ) − d (r01 + r02 − (r11 + r12 + r21 + r22 ))]
 t (1 − d )r − d ].

Thus, the cost to benefit ratio is given by
r=

(r10 + r20 − r00 )
C
=
= FP : FN loss ratio=TN:TP utility ratio,
B (r01 + r02 − (r11 + r12 + r21 + r22 ))

C =net cost (harm) of treating a subject without disease with stage one or two treatments,

B =net benefit of using stage 1 or 2 treatments to treat a subject at stage 1 or 2 of the disease.
This ratio is for rule-out patients, and then r = r RO . To distinguish between loss and utility ratio,
we have rLRO =

r10 + r20
r00
and rURO =
.
r01 + r02
r11 + r12 + r21 + r22

40
Traditionally, clinicians choose the most sensitive diagnostic test to rule-out disease and
the most specific diagnostic test to rule-in disease. In this dissertation, following Pennello (2019)
(ENAR presentation for binary screening tests), I will examine the validity of these
recommendations concerning the expected loss or expected utility of clinical consequences of
diagnostic error in multi-stage clinical conditions. I must simultaneously capture the tradeoffs
between sensitivity to each stage of the disease, specificity, disease probability, and utilities of
correct and incorrect disease classifications by the diagnostic test to determine which strategy
minimizes expected loss or maximizes expected clinical utility.
4.3.1 Expected Loss Function for Rule-In
In general, a rule-in test assesses if the results from a diagnostic test will include the
possibility that a subject has the disease of interest. A positive response (from stage 1 or 2) from
a specific test (high correct classifications of stage 0 (non-diseased)) makes the presence of the
disease (at stage 1 or 2) more likely since it is specific to that disease.
The counts in the diagnostic yield tables are the products of joint probabilities in (4.3) by
N (population size), using tables 4.1 and (4.3), and for the rule-in patient where rL =

1
rLRO

ELRI = E L(t , d ) = rL 0 10 + rL 0 20 − 1 11 −  2 22 − 1 21 −  2 12
= rL 0 ( 10 +  20 ) − 1 ( 11 +  21 ) −  2 ( 22 +  12 )
[Note: Only applicable terms are (t , d ) = (1, 0), (1,1)].
4.3.2 Expected Loss Function for Rule-Out
Similarly, based on correct classifications of the stage (1 or 2), a rule-out test emphasizes
assessing if test results will exclude the possibility that a subject is non-diseased or not in the
lower stage.
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I consider ascribing a loss rtd to the three-stage disease test result T = t on a subject with
disease state D = d where d= 0, 1 (absent and present disease stages), and t = 0, 1 (negative and
correct stage 1 and 2 of the diseases [positive test result]).
Hence, from the table (4.5), I can get
L(t , d )  t[(1 − d ) − rLRO d ]

where r RO =

(4.6)

1
, and rL are defined above, and
rL

ELRO = E L(t , d ) = 0 ( 10 +  20 ) − rLRO {1 ( 11 +  21 ) + 2 ( 22 +  12 )}
[Note: Only applicable terms are (t , d ) = (1, 0), (1,1)].
Therefore, I can find the expected loss of rule-in and rule-out as follows:

 E RI = r 0 (10 +  20 ) − 1 (11 +  21 ) − 2 ( 22 +  12 ),
(4.7)
EL =  ROL
RO
 EL = 0 (10 +  20 ) − r {1 (11 +  21 ) + 2 ( 22 +  12 )}.
Finally, (4.7) can be generalized for k-stages diseases as follows:
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GL
0 0i
L
i
0i
0 0i
L
i
ji

i =1
i =1
i =1
i =1
j =1


4.4 Expected Utility Function
Utility function tables are simply the negative of loss tables, assuming no testing cost.
Like in Pennello et al. (2016), I express utility functions as

U (t , d ) = (1 − t )U 0 (d ) + t (U1 (d ) + U 2 (d ))

= U 0 (d ) + t ([U1 (d ) + U 2 (d )] − U 0 (d ))

(4.8)

which are related directly to correct test classifications (true negative, true positive in stages 1
and 2). Since t is in the right term of (4.5) and (4.8), then modulo a constant expected loss is the
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negative of the expected utility if [( L1 (d ) + L2 (d )) − L0 (d )] = [U 0 (d ) − (U1 (d ) + U 2 (d )]. This
equality exists because, for example

[U1 (d ) + U 2 (d )] = L0 (d ) = d and U 0 (d ) = [ L1(d ) + L2 (d )] = (1 − d )r.
4.4.1 Expected Utility Functions for Rule-In
I define utility functions for rule-in as follows: from (4.8), we can get

U (t , d ) = (1 − t )(1 − d )rU + td ,
where rU =

1

rURO

, and hence the expected utility is given by

EU (t , d ) = E[(1 − t )(1 − d )rU + td ]
= rU 0 00 + 1 ( 11 +  21 ) + 2 ( 22 +  12 ),

(4.9)

[Note: Only applicable terms are (t , d ) = (0, 0), (1,1)].
4.4.2 Expected Utility Function for Rule-Out
Similarly, I define utility functions for rule-out as follows:

U 0 (d ) = (1 − d )
U1 (d ) + U 2 (d ) = rURO d .
Therefore,
E U (t , d ) = 0 00 + rURO [ 1 ( 11 +  21 ) + 2 ( 22 +  12 )], (4.10)

[Note: Only applicable terms are (t , d ) = (0, 0), (1,1)].
Note that rURO =

1
.
rU

Therefore, I have the expected utility of rule-in and rule-out as follows

 EURI = rU 0 00 + 1 (11 +  21 ) + 2 ( 22 +  12 ),
E =  RO
U  EU = 0 00 + rURO [ 1 (11 +  21 ) + 2 ( 22 + 12 )].

(4.11)
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Similarly, (4.11) can be generalized for the k-stage diseases as follows:
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4.5 Expected Relative Net Benefit
4.5.1 Relative Net Benefit of Rule-In
Based on table 4.1, I can see that evaluating expected loss can be equivalently defined as
a problem of assessing expected utility. I can say that utilities are set to the negatives of the
losses to define utility functions corresponding to the three equivalent loss functions. Upon
examining the utility and loss tables, r = FP : FN loss ratio=TN:TP utility ratio, r has been
interpreted as the overall net benefit and net cost of treating test positive subjects with and
without any stage of the disease. Under the utility function, the expected utility for the random
test is

E = Expected utility of a test
E = Expected utility of a random test with

P( R = 0) = 1- , P( R = 1) = 1 , P( R = 2) =  2 ; = 1 +  2
E p = Expected utility of perfect test ( 11 = 1, 22 = 1, 00 = 1).
Therefore, the expected net benefit for rule-in is given by

NB = E − E , where E = rU 0 00 + 1 (11 +  21 ) + 2 ( 22 + 12 ) and E = rU 0 (1 −  ) + 11 +  2 2 ,
resulting in

NB = rU 0 00 + 1 ( 11 +  21 ) + 2 ( 22 +  12 ) − [rU 0 (1 −  ) +  11 +  2  2 ]
= rU 0 ( 00 − 1 +  ) + 1 ( 11 +  21 −  1 ) + 2 ( 22 +  12 −  2 )

(4.12)
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For rule-in  = 0  1 =  2 = 0 (so we do not send the patient to treatment), then I have

NB RI = NB0 = 1 ( 11 +  21 ) + 2 ( 22 + 12 ) − rU 0 (1 −  00 ). (4.13)
Furthermore, when the test is perfect, we have (11 = 1, 22 = 1, 00 = 1, 21 = 0, 22 = 0). From
(4.13); the expected utility for the perfect test would be
NBPRI = 1 + 2 .

Therefore, the relative net benefit for rule-in can be defined as the ratio of expected utility to
perfect expected utility.

RNB RI =

NB0RI 1 (11 +  21) + 2 ( 22 + 12 ) − rU 0 (1 − 00 )
=
1 + 2
NBPRI

0
1
2
(11 +  21) +
( 22 + 12 ) −
r (1 − 00 )
1 + 2
1 + 2
1 + 2
= W1 ( 11 +  21 ) + W2 ( 22 +  12 ) − (1 −  00 )rO −1 =W1 ( 11 +  21 ) + W2 ( 22 +  12 ) − (1 −  00 )mRI ,

=

(4.14)
where, W1 + W2 = 1, W1 =

1

1 +  2

, W2 =

2

1 +  2

, mRI = rU O -1and O =

1 +  2
.
0

Like in Pennello et al. (2016), I notice that RNB RI  0 if and only if

W1 (11 +  21 ) + W2 ( 22 + 12 )  (1 −  00 )mRI , which implies that

mRI =

W1 ( 11 +  21 ) + W2 ( 22 +  12 )
( +  )
( +  )
= W1 11 21 + W2 22 12
(1 −  00 )
(1 −  00 )
(1 −  00 )

Weighted Function of TP (stage 1 or 2) of the disease

FP
which I call the Generalized Weighted Positive Likelihood Ratio (GPLR)
and W1 (11 +  21 ) + W2 ( 22 + 12 ) = (1 −  00 )mRI is the line in ROC space.
Also, I can generalize to k-stage diseases as follows: from (4.14), I have

(4.15)
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j =1

GRNB RI = Wi  ji − (1− 00 )rU OG−1 =Wi  ji − (1− 00 )mRI ,
k −1

where,

W = 1, (W =
i

i =1

i

i

, i = 1, 2,..., k − 1), mRI = rU OG−1and OG−1 =

k −1


i =1

i

0

.

k −1


i =1

i

Like in Pennello et al. (2016, 2019 ENAR), we notice that GRNB RI  0 if and only if
k −1

k −1

i =1

j =1

Wi  ji  (1− 00 )mRI , which implies that
k −1

mRI =


k −1

 W 
i =1

i

j =1

ji

(1 −  00 )

.

Weighted Function of TP (of k-stages diseases)
FP

I call the Generalized Weighted Positive Likelihood Ratio (GPLR) for the k-stage diseases
k −1

k −1

i =1

j =1

and YRI = Wi  ji = (1 −  00 )mRI is the line in ROC space.

4.5.2 Relative Net-Benefit of Rule-Out
Similarly, to find the relative net benefit for rule-out patients, I have

NB = E − E
= 0 00 + rURO [ 1 ( 11 +  21 ) +  2 ( 22 +  12 )] −  0 (1 −  ) − rURO ( 1 +  2 )
= 0 ( 00 − 1 +  ) − rURO [ ( 1 +  2 ) − 1 ( 11 +  21 ) −  2 ( 22 +  12 )]
and

NB RO = NB1 = 0 00 − rURO 1 (1 − 11 −  21 ) − rURO 2 (1 −  22 − 12 )
= 0 00 − rURO [( 1 + 2 ) − 1 (11 +  21 ) − 2 ( 22 +  12 )].

,
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This occurs where  = 1  {1 = 1 and  2 = 0} or {1 = 0 and  2 = 1} because we send the patient to
treatment, despite the disease stage. Also, I have NBPRO = 0 , when I have  00 = 1, 01 =  02 = 0
(the false-negative rate at all stages =0). Additionally, I have
RNB

RO

NB1RO 0 00 − rURO [( 1 +  2 ) − 1 ( 11 +  21 ) −  2 ( 22 +  12 )]
=
=
NBPRO
0
=  00 −

rURO [( 1 +  2 ) − 1 ( 11 +  21 ) −  2 ( 22 +  12 )]

=  00 − rURO

0
( 1 +  2 )
1
2
[1 −
( 11 +  21 ) −
( 22 +  12 )]
0
( 1 +  2 )
( 1 +  2 )

(4.16)

=  00 − m0 −1[1 − W1 ( 11 +  21 ) − W2 ( 22 +  12 )]

where [m0 = rU O1 , O1 =

0

1 +  2

].

Finally, I have RNB RO =  00 − m0 −1[1 − W1 ( 11 +  21 ) − W2 ( 22 +  12 )] . Again, I notice that RNB RO  0
if and only if  00  m0 −1[1 − W1 ( 11 +  21 ) − W2 ( 22 +  12 )] . Hence, when

m0 00 = [1 − W1 ( 11 +  21 ) − W2 ( 22 +  12 )]
W1 ( 11 +  21 ) + W2 ( 22 +  12 ) = 1 − m0 00
= 1 − m0 (1 − 1 +  00 ),
where
m0 =

[1 − W1 ( 11 +  21 ) − W2 ( 22 +  12 )]

 00



Weighted Function of FN from stage 1 and 2 of the disease
,
TN

calling it the Generalized Weighted Negative Likelihood Ratio (GNLR), I find,

W1 (11 +  21 ) + W2 ( 22 + 12 ) = 1 − m0 + m0 (1 −  00 ).
Also, I can generalize to k-stage diseases as follows: from (4.16), I have

GRNB RO =  00 −

r RO

0

k −1


i =1

i 0i
k −1

=  00 − m0 −1[ 01 +  Oi 0i ]
i =2

(4.17)
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where [m0 = ru O1 , O1 =

0

, Oi = i ; i = 2,3,..., k − 1].
1
1
k −1

Finally, I have GRNB RO =  00 − m0 −1[ 01 +  Oi 0i ] . Again, I notice that GRNB RO  0 if and only
i =2

k −1

if  00  m0 −1[ 01 +  Oi 0i ], and hence, when
i =2

k −1

m0 00 = [ 01 +  Oi 0i ]
i =2

k −1

m0 ( 00 − 1 + 1) =  01 +  Oi 0i
i =2

k −1

k −1

i =2

j =1

m0 − m0 (1 −  00 ) = (1 − ( 11 +  21 )) +  Oi (1 −  ij ),
k −1

where m0 =

[ 01 +  Oi 0i ]
i =2

 00



Weighted Function of FN in the k-stages disease
,
TN

I call it the Generalized Weighted Negative Likelihood Ratio (GNLR), with the result being
k −1

k −1

k −1

i =2

j =1

i =2

(11 +  21 ) +  Oi  ij = 1 +  Oi − m0 + m0 (1 −  00 ) is in the line in ROC space.

4.5.3 The Valid Choice of Utility Ratio r
Using (4.12), I have

NB = E − E = rU 0 ( 00 − 1 +  ) + 1 ( 11 +  21 −  1 ) + 2 ( 22 +  12 −  2 )
= −rU 0 (1 −  00 −  ) + 1 ( 11 +  21 − 1 ) + 2 ( 22 +  12 −  2 ).
For a test to have a positive net benefit NB  0 when it is

rU 0 (1 −  00 −  )  1 (11 +  21 − 1 ) + 2 ( 22 +  12 −  2 ) .
Depending on the order,  00 , ,(11 +  21 ), and ( 22 + 12 ), I have
rU 

1 ( 11 +  21 −  1 ) + 2 ( 22 + 12 −  2 )
, if   (1 −  00 ), 1  ( 11 +  21 ) and/or  2  ( 22 +  12 ), (4.18)
0 (1 −  00 −  )
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provided that 1 (11 +  21 − 1 ) + 2 ( 22 +  12 −  2 )  0 ;
rU 

1 ( 1 −  11 −  21 ) +  2 ( 2 −  22 −  12 )
, if (1 −  00 )   , 1  ( 11 +  21 ) and / or 2  ( 22 +  12 )
0 [ − (1 −  00 )]

(8.19) provided that 1 (11 +  21 − 1 ) + 2 ( 22 + 12 −  2 )  0 . The upper bound inequality is
minimized when  ,1 , 2 , and  =  1 +  2 are chosen, and such that
( +  +  +  − (1 −  00 ))
( 11 +  21 −  1 ) + ( 22 +  12 −  2 ) ( 11 +  21 +  22 + 12 −  )
. We
=
= 1 + 11 21 22 12
[(1 −  00 ) −  )
[(1 −  00 ) −  )
[(1 −  00 ) −  )

can achieve this when  = 0  1 =  2 = 0 (by never sending a patient to treatment at any stage).
This conclusion is similar to Pennello et al. (2016), so we need a trivial test to find the right
choice of ru,where the NB for a test relative to any random test remains positive. Therefore, from
(4.18), the constraint on the upper bound of ru is
rU 

1 ( 11 +  21 ) +  2 ( 22 +  12 )
. However, when the constraint for the lower bound of r
0 (1 −  00 )

for an informative test is (11 +  21 +  22 + 12 )  (1 −  00 ) , I require that the pre-test odds at any

  + 2 
1 +  2
stage of the disease  1
to eliminate random tests from
 by the lower bound r 
0
 0 
consideration. Therefore, as in Pennello et al. (2016), (4.19), no additional constraint is required.
Furthermore, for the general case, k-stage disease, the restriction on the upper bound of r is
k −1

k −1

 k −1
  i
i =1
j =1
rU 
, and on the lower bound is  i =1
0 (1 −  00 )
 0



 i  ij



.




4.5.3.1 Parametric Expressions for Utility Ratio r
As I discussed in (4.5), we derive ru (loss ratio or the utility) as follows: For rule-out
patients
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rURO =

(r10 + r20 − r00 )
C
=
= FP : FN loss ratio=TN:TP utility ratio,
B (r01 + r02 − (r11 + r12 + r21 + r22 ))

C =net cost (harm) of treating a subject without disease with stage one or two treatments,
B =net benefit of using stage 1 or 2 treatments to treat a subject at stage 1 or 2 of the disease.

Therefore, we identify r as a loss ratio by defining it rLRO = FP : FN loss ratio =

Similarly, we represent rURI = TN : TP utility ratio =

r00
. Consequently, from
(r11 + r12 + r21 + r22 )

(4.3), we have the parametric expression rLRO as follows: rLRO =

have rURO =

(r10 + r20 )
.
(r01 + r02 )

(  0 10 +  0 20 )
and for rURO we
( 1 01 +  2 02 )

0 00
.
1 ( 11 +  21 ) +  2 ( 22 +  12 )

4.6 Numerical Examples
My research considers a disease with three stages (i.e., k=3) (non-diseased, stage 1, and
stage 2 diseased). Numerical examples are conducted for the three-stage diseases, assuming
different prevalence settings, with varying parameters for the diseased underlying distributions as
shown in Table 4.2, Table 4.3, Table 4.4, and Table 4.5. To illustrate, we X1 , X 2 , and X 3 denote
biomarker values for non-diseased, stage 1, and stage 2 diseased subjects with pdfs

f1 (.), f 2 (.),and f3 (.) , respectively. In Tables 4.2-4.5, I discuss symmetric distributions and
assume that X1 N (1 ,1 ), X 2 N ( 2 , 2 ) and X 3 N ( 3 , 3 ). For illustration purposes, we use one
objective function, the Youden index (i.e., J (C ) ), to select the cut-points (C1 and C2 ) and then
calculate the values of the lower bound, the upper bound, the average, and the proposed form of
r. For each prevalence set, I consider seven different parameters for three underlying disease
distributions for various means and variances.
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Table 4.2. Settings of Parameters and Prevalences by Using Lower Bound of r for Rule-In
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Table 4.3. Settings of Parameters and Prevalences by Using Upper Bound of r for Rule-In
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Table 4.4. Settings of Parameters and Prevalences by Using the average of r for Rule-In
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Table 4.5. Settings of Parameters and Prevalences by Using Cost-Benefit Ratio r for Rule-In
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Table 4.6. Settings of Parameters and Prevalences by Using Upper Bound of r for Rule-Out
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Table 4.7. Settings of Parameters and Prevalences by Using Lower Bound of r for Rule-Out
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Table 4.8. Settings of Parameters and Prevalences by Using Cost-Benefit Ratio r for Rule-Out
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Tables 4.2-4.8 contain different numerical parameters, results of the lower bound, the
upper bound, the average, and the proposed form of r. Also, they include correct classification
rate, expected utility of rule-in and rule-out, expected loss of rule-in and rule-out, and the relative
net benefit of the rule-in and rule-out under different prevalence settings. The proposed r values
decrease when increasing  00 but decrease 11 , and  22 . This observation implies that the test is
more specific, which means that this test is better at detecting the absence of diseases and has a
positive net benefit. On the other hand, the proposed r values increase when decreasing  00 but
increasing 11 , and  22 . This observation implies that the test is more sensitive, indicating that the
test has more power to detect the presence of diseases and still has a positive net benefit.
Figures 4.1, 4.2, and 4.3 show the plots of relative net benefit for rule-in by utility ratio
(r) under different prevalence settings to gain insight into decision-theoretic benefit-risk. These
figures indicate that all chosen values of r for the lower bound, upper bound, average, and
proposed r show a similar pattern of relative net benefit (RNB) values for different prevalence
settings. However, the values of RNB are different depending on prevalence settings and the
underlying distribution set of parameters of the stages of a disease.
For the upper bound of r with different prevalence settings, r values are greater with
larger  00 but smaller 11 , and  22 , implying the test is more specific indicating that the test is
better at detecting the absence of disease. Also, I notice that the test has zero net benefits, which
is fixed for every case at the upper bound of r. The test at the upper bound of r balances benefit
to risk, and RNB will be negative if r is larger than the upper bound of r. The value of r is
increasing  td (0.599, 0.139, 0.540) if we compare it with  td (0.637, 0.196, 0.560) . This means
that larger  00 but smaller 11 , and  22 , implying the test has better specificity, better at detecting
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the absence of disease. I can also see that when all  00 ,11 , and  22 are increasing at every point,
RNB increases.
For the lower bound, the average, and the proposed r with different prevalence settings,
relative net benefit values are maximized for larger  00 ,11 , and  22 , implying the test has high
correct classification rates of disease stages. In all prevalence settings, RNB is higher for the
lower bound of r, except when the proposed value of r is smaller than the lower bound of r. The
value of r increases  td (0.599, 0.139, 0.540) if I compare it with  td (0.637, 0.196, 0.560) in
terms of net benefit, which means larger  00 , but smaller 11 , and  22 , implying the test is more
specific and has a better ability to detect the absence of disease. More specific tests enable the
health care provider not to send a patient for treatment, thus lowering the possibility of adverse
events of treating a non-diseased subject. I can also see that when all  00 ,11 , and  22 are
increasing at every point, the relative net benefit increases for every prevalence setting. Hence,
the test with higher correct classifications rates has better RNB, reducing adverse events when
treating the non-diseased and treating the correct stage of the disease.
Tables 4.6-4.8 present rule-out as the proposed utility ratio (1/r)= TN: TP values
decrease when increasing  00 but decreasing 11 , and  22 . This observation implies that the test is
more sensitive, which means that this test is better at detecting the presence of disease and has a
positive net benefit. On the other hand, 1/r values increase when they  00 decrease but

11 , and  22 increase. This observation implies that the test is more specific, indicating that the
test has more power to detect the absence of disease and still has a positive net benefit.
Figures 4.4, 4.5, and 4.6 show the plots of relative net benefit for rule-out by utility ratio
(1/r)=TN: TP under different prevalence settings to gain insight into decision-theoretic benefit-
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risk. These figures indicate that all choices of the values of 1/r for the lower bound, upper bound,
average, and proposed utility ratio (1/r)=TN: TP, which showed a similar pattern of relative net
benefit (RNB) values for different prevalence settings. However, the values of RNB are different
depending on prevalence settings and the underlying distribution set of parameters of disease
stages.
For the upper bound of r with different prevalence settings, the 1/r value is greater and
constant with larger  00 but smaller 11 , and  22 , implying the test is more sensitive indicating that
the test is better at detecting the presence of disease. Also, I notice that the test has a constant
value of 1/r, which is fixed for every case at the upper bound of r, which means the test at the
upper bound of 1/r balances the benefit to risk. Also, the RNB is changing with a constant value
of 1/r. Additionally, when all  00 ,11 , and  22 are increasing at every point, the implication is that
RNB increases.
For the lower bound, the average, and the proposed 1/r with different prevalence
settings, relative net benefit values are maximized for larger  00 ,11 , and  22 , implying the test
has high correct classification rates of disease stages. In all prevalence settings, RNB is higher
for

the

lower

bound

of

1/r.

The

value

of

the

relative

net

benefit

increases

 td (0.599, 0.139, 0.540) if I compare it with  td (0.637, 0.196, 0.560) terms of the net benefit.
This results in larger  00 but smaller 11 , and  22 , implying the test is more sensitive and has a
better ability to detect the presence of disease. More sensitive tests are most likely to send a
patient to treatment, lowering the adverse events of not treating a diseased subject. When all

 00 ,11 , and  22 are increasing at every point, relative net benefit increases for every prevalence
setting. Hence, the test with higher correct classification rates has better RNB, reducing the
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adverse events of not treating the diseased while at the same time treating the proper stage of the
disease.
Accordingly, my proposed measures have the advantage of indicating which biomarker to
be used based on the diagnostic purpose to identify rule-in or rule-out patients.
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Figure 4.1. Prevalence 1: Relative Net Benefit for Rule-In by Utility Ratio (r) = TP:TN
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Figure 4.2. Prevalence 2: Relative Net Benefit for Rule-In by Utility Ratio (r) = TP:TN
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Figure 4.3. Prevalence 3: Relative Net Benefit for Rule-In by Utility Ratio (r) = TP:TN
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Figure 4.4. Prevalence 1: Relative Net Benefit for Rule-Out by Utility Ratio (1/r)=TN:TP
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Figure 4.5. Prevalence 2: Relative Net Benefit for Rule-Out by Utility Ratio (1/r)=TN:TP
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Figure 4 6. Prevalence 3: Relative Net Benefit for Rule-Out by Utility Ratio (1/r)=TN:TP
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CHAPTER 5
REAL DATA ANALYSIS (ADNI DATA)
I use a dataset from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to
demonstrate the application of the net benefit approach to evaluating the biomarkers for the
diagnosis of Alzheimer’s Disease (AD) on its diagnostic accuracy based on a clinical
performance study, along with external information on clinical consequences. Consequently, I
describe the diagnostic yield table for the multi-stage clinical condition of Alzheimer's Disease. I
develop a decision theory based on net benefit for evaluating the biomarkers, which provides
additional interpretation for rule-in or rule-out clinical needs, as well as their adverse
consequences from unnecessary workup in multi-stage Alzheimer’s Disease.

5.1 Introduction of Alzheimer’s Disease and Dementia
Alzheimer's Disease (AD), a complex and progressive neurodegenerative disease, is the
common form of dementia among seniors. AD damages mental and memory functions and
eventually includes physical disability due to neurons' death and brain tissue deterioration. Based
on 2022 Alzheimer’s Disease Facts and Figures information, AD is one of the most common
causes of dementia, with 60% to 80% of cases occurring among 6.5 million Americans aged 65
and older. Approximately seventy-three percent are age 75 or older, and about 1 in 9 people
(10.7%) age 65 and older have Alzheimer’s Dementia. The sixth-leading cause of death in the
USA is AD. It is also predicted that every state in the United States will experience an increase
of at least 6.7% in the number of people with Alzheimer’s between 2020 and 2025, with
treatment costs increasing for patients during those years.
Dementia is a primary term that is used for describing memory impairment. Yet,
dementia due to Alzheimer’s disease is characterized by noticeable memory, language, thinking,
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or behavioral symptoms that impair a person’s ability to function in daily life. When combined
with biomarker evidence of Alzheimer's-related brain changes, these brain and behavioral
symptoms yield a more accurate Alzheimer's diagnosis ("2022 Alzheimer's disease facts and
figures," 2022). Individuals commonly experience multiple symptoms that change over time as
Alzheimer’s progresses. These symptoms represent the degree of damage to neurons in different
parts of the brain, as well as the pace at which dementia is advancing from mild to moderate to
severe, person to person. ADNI provides data that tracks the progression of Alzheimer’s disease
over time, using biomarkers and clinical measures (Alzheimer’s Disease Neuroimaging Initiative
(ADNI), 2017).
Not all individuals with evidence of Alzheimer’s-related brain changes go on to develop
symptoms of Mild Cognitive Impairment (MCI) or dementia due to Alzheimer’s. However,
people with MCI tend to have a higher risk of developing Alzheimer's or other Dementia
(Alzheimer's Association, 2020). According to Johns Hopkins Medicine (2019b), Alzheimer's
disease typically develops slowly and gradually in four general stages; preclinical stage, mild
(early stage), moderate (middle-stage), and severe (late-stage). In the preclinical stage,
individuals may have measurable brain changes that indicate the earliest signs of Alzheimer’s
disease, but they have not yet developed symptoms such as memory loss. In another study,
MAYO Clinic (2020) presents a more transitional stage: mild cognitive impairment (MCI). They
name five progressive stages; preclinical stage, mild cognitive impairment (MCI), mild
Dementia, moderate Dementia, and severe Dementia. In this application for my proposed method,
we consider three clinical disease stages for Alzheimer's disease: Cognitively Normal (nondiseased), MCI (early diseased), and dementia (fully diseased), as suggested by Alzheimer’s
Disease Neuroimaging Initiative (ADNI) (2020). The gold standard to determine AD stages is
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based on the following global clinical dementia rating (CDGLOBAL). CDGLOBAL 0, 0.5, and
1, and greater than 1 (2 or 3) indicate cognitively normal (non-diseased), MCI (early diseased),
and dementia (fully diseased), respectively.

5.2 Data Analysis
5.2.1 Data File from ADNI
The data files for this study are obtained from the Alzheimer's Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). ADNI is a global longitudinal multicenter study
that unites researchers to collect, validate and utilize data, including MRI and PET images,
genetics, cognitive tests, CSF, and blood biomarkers for early detection and tracking of the
progression of AD. The main goals of the ADNI study are to detect and track the disease's
progression with biomarkers of AD and to support AD intervention advancement, prevention,
and treatment through the application of new diagnostic methods at the earliest possible stage of
AD. It also provides all data to all scientists in the world without limitation. ADNI was started in
2004 under the leadership of Dr. Michael W. Weiner and funded as a private-public partnership
with contributions from 20 companies and two foundations. The primary goal of ADNI is to
determine the relationships between clinical, brain imaging measures, and biochemical
biomarkers through the progress of AD. It also adds brain scans that detect tau protein tangles
(tau PET), a vital indicator of the disease. ADNI also continues the discovery, optimization,
standardization, and validation of clinical trial measures and biomarkers used in AD research.
To demonstrate the application of the net benefit approach to evaluating biomarkers for
the diagnosis of multi-stage Alzheimer’s Disease based on its diagnostic accuracy and clinical
consequences of diagnostic errors, ADNI-1 data collected between September 2005 to August
2007 are included. Kersey previously used the ADNI dataset to measure diagnostic accuracy
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with cut-point criteria for multi-stage diseases based on concordance and discordance (Kersey,
Samawi, Yin, Rochani, & Zhang, 2022). I am using the same dataset to compare biomarkers of
Alzheimer’s Disease by using our proposed approach. The dataset consists of 415 subjects with
114, 256, and 45 subjects for the non-diseased (Cognitively Normal, or CN), the early diseased
(Mild Cognitive Impairment, or MCI), and the fully diseased (Dementia) groups, respectively.
The data file presents test results from five core biomarkers for Alzheimer's disease,
including three biomarkers from core cerebrospinal fluid (CSF) and two from magnetic
resonance imaging (MRI). Blennow, Hampel, Weiner, and Zetterberg (2010) summarize that the
core CSF biomarkers reflect AD pathology, evaluate disease risk or prognosis, and have high
diagnostic accuracy when diagnosing AD with dementia and prodromal AD in mild cognitive
impairment cases, along with monitoring therapeutic interventions on previous studies (Das,
Murphy, Younkin, Younkin, & Golde, 2001; Garcia-Alloza et al., 2009; Levites et al., 2006).
The data file includes results of total tau (TAU), phosphorylated tau (PTAU), and the 42 amino
acid form of amyloid- (ABETA142). These three CSF biomarkers are the central pathogenic
processes in AD and have been proposed as candidate markers for predicting cognition decline
as the progression indicator of dementia. Previous studies also discuss the other two potential
biomarkers of Alzheimer's disease measured from MRI: rate of volume change of the
Hippocampus and whole brain. Imaging has a significant role in improving our understanding of
this disease. Studies present the relationship between volume change and the initiative of
Alzheimer's disease and how these biomarkers change over time, relating to the injury and death
of neurons (Duthey, 2013; Grundman & Delaney, 2002; Shaffer et al., 2013).
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5.2.2 Biomarker Selection
ADNI uses five core biomarkers to help predict the onset of AD over the progression of
clinical disease stages. I am interested in biomarkers of Alzheimer's disease measured from CSF
variables, including ABETA142, PTAU, and TAU. I also include in our analysis the other two
potential biomarkers of Alzheimer's disease measured from MRI, including hippocampus
volume and brain volume, because these biomarkers are related to the severity of cognitive
impairment (Vijayakumar & Vijayakumar, 2013).
5.2.3 Analysis of ADNI Data
I apply the generalized Youden index (GYI) measure of diagnostic accuracy to ADNI-1
data. I also apply GYI criteria for cut-point selection to the dataset to find the corresponding
optimal cut-points. Using the gold standard in the dataset (CDGLOBAL), the prevalence of
Alzheimer’s disease in different stages is approximated as 0.72( p1 ), 0.2( p2 ), and 0.08( p3 ) for
stages 1, 2, and 3, respectively, where p1 , p2 , and p3 are the prevalence of stage 1 (CN), stage 2
(MCI), and stage 3 (Dementia), respectively, based on estimates from Kantarci et al. (2009);
Mitchell and Shiri‐Feshki (2009); Roberts and Knopman (2013).
My primary goal is to illustrate the application of the net benefit approach to evaluating
the five biomarkers of interest: hippocampus volume (Hippocampus), brain volume
(WholeBrain), Total tau (TAU), Aβ1-42 (ABETA142), and p-tau181 (PTAU181P) of
Alzheimer's disease based on diagnostic accuracy and clinical consequences of diagnostic errors.
Another goal is to compare those biomarkers using my proposed measure based on the
diagnostic purpose to identify rule-in or rule-out patients. I use the correct classification rate
(CCR) for each stage, misclassification rates over three stages, and the benefit and the loss to
evaluate the performances of the biomarkers of interest using the above-proposed methods. I
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calculate the values of the lower bound, the upper bound, and the proposed form of the CostBenefit Ratio (r). I also calculate the expected utility for rule-in and rule-out, expected loss for
rule-in and rule-out, and relative net benefit for rule-in and rule-out to evaluate the benefits of the
five biomarkers of interest.
5.2.4 Results of ADNI Data
The dataset consists of a total of 415 subjects with 114, 256, and 45 subjects for the nondiseased (Cognitively Normal, or CN), the early diseased (Mild Cognitive Impairment, or MCI),
and the fully diseased (Dementia) groups, respectively. The actual sample sizes for biomarkers in
the dataset may vary and are smaller than the group sizes due to some missing values. Table 5.1
presents the summary descriptive statistics of the five interested biomarkers in the ADNI dataset.
Table 5.1 shows that Hippocampus, WholeBrain, and ABETA142 average values decrease as the
severity of the disease increases. This indicates that the lower the value of the biomarker is, the
more severe the disease is. In contrast, the average values of the rest biomarkers, including
PTAU181P and TAU, increase when the disease progresses to later stages.
Table 5.1. Summary of Descriptive Statistics of Five Biomarkers (source: Kersey et al., 2022)

The optimal statistics of GYI are calculated, and corresponding optimal cut-points

(c1 and c2 ) are shown in Table 5.2. Based on estimated statistics, the five biomarkers are ranked
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in Table 5.3. The best biomarker is Hippocampus using the GYI measure of diagnostic accuracy,
followed by ABETA142, PTAU181P, TAU, and WholeBrain. Hippocampus has the highest
estimated GYI measure of diagnostic accuracy among the five biomarkers. Thus, Hippocampus
is the best biomarker to use to discriminate subjects among the three clinical stages of
Alzheimer's disease. WholeBrain is the least favorable biomarker to use to distinguish subjects
among the three stages of Alzheimer's disease.
Table 5.2. Estimated Optimal Statistics and Corresponding Cut-points for Five Biomarkers

Table 5.3. The Rank of Biomarkers with Different Diagnostic Measures

Correct classification rates ( p11, p22 , and p33 ) and corresponding misclassification rates

( p01, p02 , p10 , p12 , p20 , and p21 ) of the five interested biomarkers are calculated and presented in
Table 5.4. The estimated optimal cut-points c1 and c2 of ABETA142 and PTAU181P using GYI
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measure criteria are identical. The corresponding correct classification rates for the second class
(the early diseased or Mild Cognitive Impairment) are zeros. These results show no subject was
correctly diagnosed with Mild Cognitive Impairment by the GYI criterion. Such results imply
that ABETA142 and PTAU181P are not suitable biomarkers to distinguish early disease stage
patients if using the GYI criterion. The nature of Hippocampus and WholeBrain biomarkers
show the average values of these two biomarkers decrease as the severity of the disease increases.
For this reason, the optimal statistics of the reciprocal of Hippocampus and WholeBrain using
GYI are calculated, and corresponding optimal cut-points (c1 and c2 ) are shown in Table 5.5.
Consequently, correct classification rates ( p11, p22 , and p33 ) and corresponding misclassification
rates ( p01, p02 , p10 , p12 , p20 , and p21 ) of these two biomarkers are calculated and presented in
Table 5.6. The correct classification rates, and corresponding misclassification rates of
Hippocampus, WholeBrain, using GYI measure criteria, are the same as the correct classification
rates and corresponding misclassification rates of the reciprocal Hippocampus and WholeBrain
biomarkers using GYI measure criteria. I could see that the results are not affected by taking the
reciprocal biomarkers. Thus, Hippocampus is the best biomarker, and WholeBrain is the least
favorable biomarker to discriminate between subjects among the three stages of Alzheimer's
disease.
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Table 5.4. The Corresponding Misclassification Rates for Five Biomarkers

Table 5.5. Estimated Optimal Statistics and Corresponding Cut-points for Biomarkers

Table 5.6. The Corresponding Misclassification Rates for Reciprocal Biomarkers

The expected utility of rule-in and rule-out, expected loss of rule-in and rule-out, the
relative net benefit of rule-in and rule-out using the lower bound, upper bound, and proposed
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form of r for the five interested biomarkers are calculated and presented in Tables 5.7 to 5.9
respectively.
Table 5.7. Expected Utility, Expected Loss, Relative Net Benefit Using Lower Bound of r

Table 5.8. Expected Utility, Expected Loss, Relative Net Benefit Using Upper Bound of r
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Table 5.9. Expected Utility, Expected Loss, Relative Net Benefit Using Proposed Form of r

Based on the relative net benefit for rule-in and rule-out with different forms of r, the five
biomarkers are ranked in Tables 5.10-5.11. For example, the relative net benefit for rule-in and
rule-out with a lower bound of r, the best biomarker is Hippocampus, followed by ABETA142,
PTAU181P, and TAU. Hippocampus has the highest relative net benefit among the five
biomarkers for all three forms of r. Thus, Hippocampus is the best biomarker to discriminate
between subjects among the three stages of Alzheimer's disease. All three forms of r agree that
WholeBrain is the least favorable biomarker. In both rule-in and rule-out of the disease,
ABETA142, PTAU181P, and TAU are ranked very differently using the three forms of r, while
Hippocampus, ABETA142, PTAU181P, and TAU are consistent for the lower bound of r. The
best biomarker for the proposed form of r is Hippocampus for rule-in, followed by TAU,
ABETA142, PTAU181P, and WholeBrain. However, for the proposed form of a risk-benefit
ratio (r), the best biomarker is Hippocampus for rule-out, followed by ABETA142, PTAU181P,
TAU, and WholeBrain. In this sense, the proposed form of a risk-benefit ratio (r) performs better
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than other forms of r for deciding which biomarker to use based on the diagnostic purpose to
identify rule-in or rule-out patients.
Table 5.10. The Rank of Biomarkers for Rule-In with Different Forms of r

Table 5.11. The Rank of Biomarkers for Rule-Out with Different Forms of r

Figures 5.1 and 5.2 show the relative net benefit of the biomarkers of interest for rule-in
and rule-out by the proposed risk-benefit ratio. In this case, Hippocampus is the best biomarker
that can discriminate between subjects among the three stages of Alzheimer's disease, and
WholeBrain is the least favorable biomarker.
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Figure 5.1. Relative Net Benefit of Biomarkers for Rule-In by Proposed Utility Ratio (r)
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Figure 5. 2. Relative Net Benefit of Biomarker for Rule-Out by Proposed Utility Ratio (1/r)
The relative net benefit over never-treat and always-treat policies can be plotted as
relative importance (risk-benefit) ratio r to compare the biomarkers (Figures 5.3–5.4). These
plots indicate that the relative net benefit over the never-treat policy is noticeably worse for the
WholeBrain than the Hippocampus over an extensive range of r values. In contrast, the relative
net benefit over the always-treat policy for WholeBrain is still worse than Hippocampus over a
comprehensive range of r values. Thus, the two tests can be considered comparable in settings
where prophylactic treatment is practiced in place of testing.
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Figure 5.3. Relative Net Benefit over Never-Treat Utility Ratio (r)
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Figure 5.4. Relative Net Benefit over-Always Treat Utility Ratio (r)
Based on the proposed form of r, Hippocampus is the best biomarker to discriminate
between subjects among the three stages of Alzheimer's disease. I illustrate these results with the
Likelihood Ratio Graph (Figure 5.5), a helpful display proposed by Biggerstaff (2000). The
graph has similar axes to the ROC plot. The coordinate of the biomarker's true and false-positive
fractions is plotted in the graph. The biomarker is plotted with two lines on the ROC plot with
PLR and NLR, respectively. The two lines define four regions in which the coordinate of the
biomarker could lie.
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Consequently, the biomarker coordinates of TPR and FPR fall in region A, indicating
that the biomarker is better at detecting the absence of Alzheimer's disease than the
Hippocampus but worse at detecting its presence because its PLR is worse (smaller). Still, its
NLR is better (smaller). The evaluation of which biomarker is better based on test accuracy alone
is equivocal.

Figure 5.5. Likelihood Ratio Graph: Regions of Comparison
Comparing the diagnostic yield of biomarkers reveals several insights (Table 5.12- Table
5.16). The results represent positive test counts by disease status. In the table, clinical
consequences are explored, assuming that a subject testing positive would be referred to an
additional procedure that puts him or her at risk for adverse events. Also, I compare tests based
on benefit-risk in a decision-theoretic framework. I assign losses to test misclassifications or
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utilities to correct classifications equivalently. The theory provides additional interpretations of
quantities in the diagnostic yield table. In addition to the number of FP subjects harmed from
unnecessary additional workup involving an invasive procedure, I can quantify the number of FN
subjects harmed by lack of further workup. The harm associated with an FN result includes not
receiving necessary treatment for a disease that may progress unattended. The disease is typically
aggressive in some settings, and all FN subjects are harmed by lack of detection.
Table 5.12. Diagnostic Yield of Hippocampus biomarker for Alzheimer's disease

Table 5.13. Diagnostic Yield of Whole-Brain biomarker for Alzheimer's disease
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Table 5.14. Diagnostic Yield of ABETA142 biomarker for Alzheimer's disease

Table 5.15. Diagnostic Yield of PTAU181P biomarker for Alzheimer's disease

Table 5.16. Diagnostic Yield of TAU biomarker for Alzheimer's disease

5.3. Discussion
Based on the optimal statistics in Table 5.2, Hippocampus has the highest statistics
compared to other biomarkers. Also, the plots show that Hippocampus has the most distinct
distribution curve among the three clinical stages.
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The optimal cut-points of Abeta and PTAU selected by GYI are identical, and the correct
classification rate at the early disease stage is zero for both biomarkers. The results imply that
Abeta and PTAU are not suitable biomarkers for detecting between subjects among the three
stages in this study. However, the optimal statistics of these two biomarkers are close to the
optimal statistics of TAU and slightly higher than the optimal statistics of WholeBrain. The
optimal statistic of TAU lies between the values of Abeta and PTAU, and it is somewhat higher
than the optimal statistics for the whole-Brain. Hippocampus has much higher optimal statistics
than other biomarkers. Thus, Hippocampus is the best biomarker to use to discriminate between
subjects among the three stages of Alzheimer's disease. It is important to properly diagnose
subjects in the early stage of Alzheimer's disease since it is an irreversible condition that
progresses over time, and brain changes caused by Alzheimer's disease may begin 20 years or
more before any signs and symptoms appear (Gaugler, James, Johnson, Marin, & Weuve, 2019).
Early diagnosis, intervention, prevention, and treatment by application of new diagnostic
methods at the earliest possible stage of AD are essential in slowing down the progression of the
disease. Gaugler et al. (2019) mention that seniors believe the early diagnosis is important
because of early intervention for the disease, allowing them time to understand what is
happening with the disease and all concerned. This helps them to adjust and offers access to
advice, financial support, and non-pharmacological and pharmacological treatments, allowing
the family to plan for the future. Compared to existing measures, our proposed measure has high
correct classification rates of stage 1 and stage 2, the specificity of stages 1 and 2, along with the
sensitivity of stages 1 and 2, respectively, for the Hippocampus. The specificity of stages 1 and 2
emphasizes rule-in information and provides essential information for the early diagnosis of
Alzheimer's disease. The sensitivity for stages 1 and 2 highlights rule-out information and
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provides crucial information to avoid unnecessary additional workup of Alzheimer's disease
early on.
In conclusion, the net benefit approach is the most effective approach to evaluating
biomarkers of Alzheimer's disease when using the Hippocampus as the biomarker for early
diagnosis for subjects in stage 1 and stage 2. Its classification rates in early diagnosis are the
highest. In summary, among the five biomarkers, Hippocampus has presented the best
performance results in the scenario of a three-stage setting, while Abeta has presented an
acceptable performance in the two-stage setting.
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CHAPTER 6
FINAL REMARKS, CONCLUSIONS, LIMITATIONS, AND
FUTURE RESEARCH
6.1 Final Remarks and Conclusions
Comparing tests based on benefit-risk plays a crucial role in convincing clinicians
because it involves the accuracy of the test and the clinical consequences of diagnostic errors.
Evaluating diagnostic tests is essential in placing patients on appropriate treatment plans; thus,
measuring the benefit-risk of a test has significant clinical implications. In my study, benefit-risk
approaches are used for binary tests, where benefit and harm are put on the same scale to
determine whether a diagnostic test has better, worse, or the same outcomes when assessing a
test's clinical consequences. No studies have investigated the accuracy of measures and the
clinical consequences of the medical diagnostic test errors in multi-stage disease settings.
However, the clinical implications of treating or not treating patients at a different stage of the
disease have different benefit-risk consequences. In practice, it is vital to detect the early stage of
illness for timely medical interventions to reduce the cost of the treatment and improve the
quality of life for patients. Diagnostic tests that can identify multiple stages are precious,
desirable, and in need. As I have studied, I have realized that the benefit-risk approach for multistage diseases requires more research than two-stage diseases.
Motivated by Pennello's approach, this dissertation proposes a descriptive, diagnostic
yield table for multi-stage clinical conditions in practice. I extend the net benefit approach of
evaluating diagnostic tests to multi-stage clinical conditions. Consequently, I extend the
diagnostic yield table to multi-stage clinical conditions. I develop a decision theory based on net
benefit for evaluating diagnostic tests. It provides additional interpretation for rule-in or rule-out
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clinical conditions and their adverse consequences from unnecessary work-up in multi-stage
diseases. Numerical examples are conducted for the three-stage disease to illustrate the proposed
measures, assuming different prevalence settings with varying parameters for the diseased
underlying distributions. Numerical examples show that the higher correct classification rates
test has a better relative net benefit. Consequently, it will reduce adverse events by treating the
non-diseased and helping to avoid not treating the right stage of the disease. My results indicate
that using our proposed research methods will yield the advantage of most effectively deciding
which biomarker should be used based on the diagnostic purpose to identify rule-in or rule-out
patients.
This study also provides an example of applying the proposed measure for multi-stage
diseases, using a dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Results
concur with the numerical study and highlight the strengths of the proposed measure that benefits
and risks could be different from stage to stage. This study provides clues for the early diagnosis
of Alzheimer's disease. For example, the net benefit approach of evaluating diagnostic tests can
detect subjects in the first and the second stages with the highest correct classification rates in
these two stages of the biomarkers. This study provides exciting exploratory outcomes in
improving both diagnostic accuracy tests and the clinical consequences of diagnostic error for
multi-stage diseases, especially for those who want to discover biomarkers for early diagnosis.

6.2 Limitations and Future Work
In this study, the net benefit approach has shown some advantages in detecting subjects
in the last stage of a multi-stage disease and has been beneficial for diagnosis; however, the
correct classification rate has been found to be slightly lower in the last stage of the disease.
Additionally, when comparing the benefit-risk among all disease stages, I have found that there
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can be no existing standardized methods to compare the performance of the measures since they
have different properties. For two-stage diseases, high correct classification rates in both stages
are desired. For multi-stage disease cases, the demand for a high correct classification rate of a
specific stage relies on clinical needs, clinical consequences, and treatment cost. For example,
when a clinical test or biomarkers are considered to identify subjects in the early stages, the
correct classification rates are expected to be as high as needed. In contrast, when a clinical test
or biomarkers are considered to identify patients in late stages, the correct classification rate of
the last stage would be more critical than the others. In reality, it is hard to achieve a balanced
diagnostic test or biomarker with high correct classification rates among all stages. Hence, a
method that can evaluate the performance of diagnostic test accuracy and clinical consequences
of diagnostic errors, besides the benefit-risk, is desired in future studies.
Mainly the focus of this study is on the ordinal stages of diseases. But many cases of
disease deal with multiple nominal classes, including genomic studies. Additional research is
needed for nominal cases, including a general outline of specific benefit-risk comparisons of
tests that permit multiple nominal test results.
Furthermore, the findings of this study's estimations are restricted to using the kernel
approach. The simulation of estimation using other methods is highly encouraged to compare the
performance of diagnostic test accuracy and clinical consequences of the diagnostic errors of
multi-stage disease. Additional research is needed into the properties and strengths of different
measures under various distributions.
Diagnosis of multi-stage disease at an early stage provides enough time for health care
practitioners to make a plan, fight severe diseases, and minimize the cost, specifically for
conditions without a cure. However, I have found a lack of practical applications of net benefit
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analysis of diagnostic tests for multi-stage diseases to research data. Therefore, there is a top
priority to develop reliable and reasonable measures to compare diagnostic test accuracy and
clinical consequences of diagnostic errors, which will further improve diagnosis and assist in
designing clinical treatments and guidelines.
Lastly, a single biomarker is less than satisfactory for confirmation of the clinical
diagnosis of a disease. For example, genetic and epigenetic biomarkers are not enough to identify
the subtypes of cancer or confirm the staging of cancer patients and treatment evaluation. As a
result, the generalization of single biomarker measures to multiple biomarkers is encouraged for
future study of the diagnosis of multi-stage diseases.
Although the net benefit approach is relatively novel, the net benefit of comparing
diagnostic tests has recently gained increasing attention. Unlike traditional measures such as
sensitivity, specificity, or area under the curve, studying net benefit provides information about
the clinical judgment of the relative value of benefit and harm associated with diagnostic errors
(Vickers, Van Calster, & Steyerberg, 2016). This approach helps doctors make better decisions
and make wider use of net benefits. It also quantifies the good and harm of a clinical decision
based on a biomarker, diagnostic test, or statistical model and better matches the clinical aim of
much medical research. As a result, the broader use of the net benefit approach should be an
exciting focus in the future study of the diagnosis of multi-stage diseases.
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